Pfizer: reassures on outcome of Zantac case

(CercleFinance.com) - Since February 2020, a number of lawsuits have been filed against several defendants, including Pfizer, involving Zantac, an antihistamine used in the treatment of peptic ulcer and gastroesophageal reflux disease, which is alleged to contain a potential carcinogen.


In this context, the laboratory states that it only sold Zantac between 1998 and 2006. Therefore, the withdrawal of Zantac products from the market in 2019 and 2020 did not involve any Pfizer product.

Pfizer says it has significant defences to the litigation and that there are important legal and factual issues that remain to be resolved by the courts. As a result, it currently believes that the outcome of litigation is unlikely to be material for Pfizer.



Copyright (c) 2022 CercleFinance.com. All rights reserved.